Products for Research Use Only
RegisterLogin

Rafutrombopag

CAT: 0804-HY-145589Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145589Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease[1][2][3].
CAS Number
2600513-51-5
Product Name Alternative
Hetrombopag; SHR-8735
UNSPSC
12352005
Target
Apoptosis; CDK; ERK; PI3K; STAT; Thrombopoietin Receptor
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Neuroscience-Neuromodulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/rafutrombopag.html
Solubility
10 mM in DMSO
Smiles
O=C1N(N=C(/C1=N/NC2=C(C(C3=CC=C(C(O)=O)O3)=CC=C2)O)C)C4=CC=C(CCCC5)C5=C4
Molecular Formula
C25H22N4O5
Molecular Weight
458.47
References & Citations
[1]Xie C, et al. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med. 2018 Nov;22 (11) :5367-5377.|[2]Zhou N, et al. Hetrombopag, a Thrombopoietin Receptor Agonist, Protects Cardiomyocyte Survival from Oxidative Stress Damage as an Enhancer of Stem Cells. Cardiovasc Drugs Ther. 2016 Dec;30 (6) :567-577.|[3]Zhao Yufei MD, et al. Hetrombopag, an Emerging Iron-Chelating Agent, Alleviates Systemic Iron Overload. 2024 Nov. Page 3848, ISSN 0006-4971.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 4
Isoform
CDK4; CDK6; PI3K

Alternative Products

CatalogName
MBS5805543Rafutrombopag

Popular Products